Literature DB >> 29117395

Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.

.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 29117395     DOI: 10.1093/jnci/djx173

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Aaron N Winn; Ethan Basch; Nancy L Keating
Journal:  JAMA Oncol       Date:  2018-06-14       Impact factor: 31.777

2.  BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours.

Authors:  Pashtoon Murtaza Kasi; Sakti Chakrabarti; Sarah Sawyer; Michael Krainock; Andrew Poklepovic; George Ansstas; Minu Maninder; Meenakshi Malhotra; Joe Ensor; Ling Gao; Zeynep Eroglu; Sascha Ellers; Paul Billings; Angel Rodriguez; Alexey Aleshin
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006

3.  Factors Associated With Use of High-Cost Agents for the Treatment of Metastatic Non-Small Cell Lung Cancer.

Authors:  Cathy J Bradley; Megan Eguchi; Marcelo C Perraillon
Journal:  J Natl Cancer Inst       Date:  2020-08-01       Impact factor: 13.506

4.  Cost Savings Analysis of Individualized Exercise Oncology Programs.

Authors:  Karen Y Wonders; Rob Wise; Danielle Ondreka; Josh Gratsch
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.